Sofinnova Investments

Profile

Sofinnova: At the Intersection of Life Science, Finance & Innovation
Since our founding in 1976, Sofinnova has been active in life science investing and has primarily focused on therapeutic drugs over the last decade. We are a clinical-stage biopharmaceutical investment firm with approximately $2.6B in assets under management and committed capital.* We invest in both private and public equity of therapeutics-focused companies.

Our Mission: to improve the lives of patients through science. We strive to provide outstanding results for those we serve: patients, entrepreneurs, and the investors that entrust us with their capital.

Historically Helping
We are long-term investors with an extensive track record of helping the world’s most transformative therapies come to fruition. From drug development and navigating the regulatory process to company building and IPO, we strive to be collaborative, meaningful board members, and excellent partners at every level.

Exploring Possibilities
Sofinnova invests in late preclinical and clinical therapeutic companies across the U.S. and Europe. Key therapeutic areas include oncology, respiratory, dermatology, ophthalmology, neurology and women’s health. We actively partner with entrepreneurs in both the U.S. and Europe who want to rewrite the quality of healthcare today for a better life tomorrow.

One Name, Two Firms
Sofinnova began in 1976 as the U.S. affiliate of the Paris-based Sofinnova Partners. In 1997, the two firms split to become independent entities. Sofinnova Ventures in the US and Sofinnova Partners in France. In 2007, Sofinnova Ventures further refined the investment strategy to be primarily focused on investing in private biopharmaceuticals companies. In 2017, we introduced a public equity strategy focused on global therapeutics. Subsequently, in 2019, we changed our name to Sofinnova Investments to reflect having both public and private strategies in biopharmaceuticals.

Sofinnova Investments: Funding Tomorrow’s Cures.